Kyverna Therapeutics: Strong Clinical Progress and Regulatory Alignment Support Buy Rating

In a report released on May 13, Thomas Smith from Leerink Partners reiterated a Buy rating on Kyverna Therapeutics, Inc. (KYTX – Research Report), with a price target of $25.00.

Thomas Smith’s rating is based on Kyverna Therapeutics’ strong clinical progress and strategic alignment with regulatory authorities. The company has successfully completed enrollment for its Phase 2 trial of KYV-101 in patients with stiff person syndrome, with expectations for meaningful clinical improvements. Additionally, Kyverna has received alignment from the FDA for a registrational Phase 3 trial in myasthenia gravis, indicating regulatory confidence in their development pathway.
Furthermore, the company’s manufacturing plans have been endorsed by the FDA, ensuring readiness for commercial production. Upcoming data from ongoing trials in lupus nephritis and myasthenia gravis, along with a planned virtual event to discuss neuroinflammation treatment efforts, underscore the company’s robust pipeline and potential for future growth. These factors collectively support the Buy rating.

In another report released yesterday, Morgan Stanley also reiterated a Buy rating on the stock with a $20.00 price target.